ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status

Inflammasome inhibitors have moved into P2 trials based on preclinical/P1 safety data & promising signals of efficacy. Data read-outs expected beginning H1